Welcome to our dedicated page for Onco-Innovations news (Ticker: ONNVF), a resource for investors and traders seeking the latest updates and insights on Onco-Innovations stock.
News for Onco-Innovations Limited (ONNVF) centers on its activities in oncology research, preclinical drug development, AI-enabled precision medicine, and corporate financing. The company describes itself as a Canadian-based oncology-focused organization with an exclusive worldwide license to patented technology targeting solid tumours, including its PNKP Inhibitor Technology platform.
Investors and observers following Onco-Innovations’ news can expect updates on the advancement of its PNKP Inhibitor Technology (A83B4C63), including manufacturing milestones with Dalton Pharma Services such as process optimization, intermediate scale-up, analytical method development, and preparation for potential future clinical material production. Releases also cover collaborations with partners like Kuano Ltd., where quantum-ready molecular modelling and AI-driven compound design are being applied to deepen understanding of PNKP inhibition and guide next-generation therapeutic candidates.
Another important stream of news involves Onco-Innovations’ subsidiary Inka Health and its SynoGraph platform. Announcements have highlighted publications on the transportability of real-world evidence, integration of advanced statistical methods into SynoGraph, and participation in precision oncology forums with organizations such as Colorectal Cancer Canada. These items illustrate how the company links AI, real-world data, and oncology decision-making.
Corporate and capital markets developments also feature in the news flow. Onco-Innovations has reported private placements, board appointments, marketing engagements, and its intention to pursue a potential Nasdaq cross-listing with the support of a U.S. investment bank. For a consolidated view of these scientific, strategic, and financing updates, this news page provides a single location to review the company’s disclosed developments over time.
Onco-Innovations (OTCQB:ONNVF) announced that its subsidiary, Inka Health, filed a provisional patent application with the USPTO for SynoGraph, its next-generation AI platform, on January 28, 2025. The application, titled 'Method and System for Causal Graph Generation and Analysis,' aims to protect their AI-driven precision medicine approach.
SynoGraph utilizes AI-powered causal inference to identify cancer patients likely to respond to specific treatments. The platform integrates various medical data types including genomics, transcriptomics, and proteomics to uncover insights for treatment decisions and clinical trial design. The technology is expected to enhance Onco's drug research initiatives by potentially streamlining trial design and patient selection, which could reduce development costs and improve patient outcomes.
Onco-Innovations (CSE:ONCO)(OTCQB:ONNVF)(Frankfurt: W1H) has announced the commencement of trading its common shares on the OTCQB marketplace under the symbol 'ONNVF'. The company will maintain its listing on the Canadian Securities Exchange under 'ONCO'.
This strategic move to the OTCQB Venture Market is designed to enhance the company's visibility and accessibility to U.S. investors, potentially expanding its shareholder base. CEO Thomas O'Shaughnessy emphasized that this listing represents a significant milestone for the company's growth strategy in driving oncology innovation.
The OTCQB Venture Market provides a platform for early-stage and growth companies to increase their U.S. market presence, with real-time quotes and market information available at otcmarkets.com.